Business Context and Reporting Period
This Form 8-K filing by Anteris Technologies Global Corp. (AVR) covers the reporting period of November 26, 2025. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Toowong, Australia.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document explicitly states that the termination of the agreement discussed does not materially impact the Company's financial results.
Material Changes
On November 26, 2025, the Company notified 4C Medical Technologies, Inc. ("4C") of its decision not to renew the Second Amended and Restated Supply and License Agreement. Key details include:
- Agreement Scope: The agreement covered the supply of ADAPT tissue for 4C's transcatheter mitral and tricuspid valve regurgitation therapy devices and a limited license for related sterilization methods.
- Termination Terms: The agreement was set to expire on June 1, 2026, with automatic renewal provisions. The Company provided notice 180 days prior to the expiration date as required.
- Financial Impact: The Company will not incur any early termination penalties, and the termination is not expected to materially impact financial results.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, updated outlook, or specific risk factors beyond the disclosed termination of the supply agreement. Management commentary is limited to the factual notification of non-renewal and the confirmation of no financial penalty.
Investor Verification Checklist
- Verify the Company's future supply agreements for ADAPT tissue to replace the terminated contract with 4C Medical Technologies.
- Confirm the actual revenue contribution of the 4C agreement in prior periods to validate the claim of "no material impact."
- Monitor subsequent filings for any changes in the Company's strategic direction regarding transcatheter valve therapies.